{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:29:51Z","timestamp":1780612191716,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001513","name":"Breast Cancer Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001068","name":"Dana Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001068","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G Komen Breast Cancer Foundation","doi-asserted-by":"publisher","award":["CCR19608265"],"award-info":[{"award-number":["CCR19608265"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G Komen Breast Cancer Foundation","doi-asserted-by":"publisher","award":["CCR21663667"],"award-info":[{"award-number":["CCR21663667"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.esmoop.2025.105568","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T01:52:18Z","timestamp":1756432338000},"page":"105568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy"],"prefix":"10.1016","volume":"10","author":[{"given":"A.","family":"Strahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Raghavendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.B.","family":"Zakon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cherian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vincuilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.C.C.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Tayob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.G.","family":"Stover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.","family":"Barcenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5989-6636","authenticated-orcid":false,"given":"A.C.","family":"Garrido-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2025.105568_bib1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10549-023-07114-8","article-title":"National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial","volume":"203","author":"Rogers","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105568_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamaoncol.2020.7310","article-title":"Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial","volume":"7","author":"Filho","year":"2021","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105568_bib3","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105568_bib4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.esmoop.2025.105568_bib5","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"issue":"9938","key":"10.1016\/j.esmoop.2025.105568_bib6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105568_bib7","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.esmoop.2025.105568_bib8","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105568_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105568_bib10","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105568_bib11","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2013College of American Pathologists Guideline Update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2025.105568_bib12","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1200\/JCO.20.03613","article-title":"Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105568_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1515\/ijb-2012-0030","article-title":"A weighting analogue to pair matching in propensity score analysis","volume":"9","author":"Li","year":"2013","journal-title":"Int J Biostat"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105568_bib14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/14656566.2024.2337261","article-title":"Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study","volume":"25","author":"Ta\u015f\u00e7\u0131","year":"2024","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105568_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.19.00904","article-title":"Phase III trial of adjuvant capecitabine after standard neo-\/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM\/2003-11_CIBOMA\/2004-01)","volume":"38","author":"Lluch","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105568_bib16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/1078-0432.CCR-22-2191","article-title":"Triple-negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine","volume":"29","author":"Asleh","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105568_bib17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jama.2020.23370","volume":"325","author":"Wang","year":"2021","journal-title":"J Am Med Assoc"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105568_bib18","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1200\/JCO.21.00976","article-title":"Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131","volume":"39","author":"Mayer","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105568_bib19","article-title":"Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer","volume":"41","author":"Lin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105568_bib20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12916-022-02516-9","article-title":"A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society","volume":"20","author":"Li","year":"2022","journal-title":"BMC Med"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105568_bib21","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1200\/JCO.23.01730","article-title":"Topical diclofenac for prevention of capecitabine-associated Hand\u2013Foot syndrome: a double-blind randomized controlled trial","volume":"42","author":"Santhosh","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105568_bib23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105568_bib24","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1038\/s41467-024-46961-x","article-title":"Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study","volume":"15","author":"Lynce","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105568_bib25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.2020.23371","article-title":"Adjuvant capecitabine in triple-negative breast cancer: new strategies for tailoring treatment recommendations","volume":"325","author":"Parsons","year":"2021","journal-title":"J Am Med Assoc"},{"issue":"15 Pt 1","key":"10.1016\/j.esmoop.2025.105568_bib26","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:59:28Z","timestamp":1772895568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925014371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2059702925014371"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105568","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105568"}}